TY - JOUR
T1 - Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia
AU - Cortes, Jorge
AU - Tsimberidou, Apostolia M.
AU - Alvarez, Ricardo
AU - Thomas, Deborah
AU - Beran, Miloslav
AU - Kantarjian, Hagop
AU - Estey, Elihu
AU - Giles, Francis J.
PY - 2002
Y1 - 2002
N2 - Purpose: Mylotarg, a humanized anti-CD33 antibody linked to an antitumor antibiotic, is approved for the treatment of patients with relapsed acute myeloid leukemia (AML). Topotecan and cytarabine (ara-C) is an effective anti-AML regimen. A pilot study of Mylotarg combined with topotecan and ara-C (MTA) was conducted in patients with refractory AML. Methods: MTA consisted of Mylotarg 9 mg/m2 intravenously (i.v.) over 2 h on day 1, ara-C 1 g/m2 over 2 h i.v. on days 1 through 5, and topotecan 1.25 mg/m2 by continuous infusion i.v. on days 1 through 5. Results: A group of 17 patients (9 primary resistant, 8 relapsed) with AML or advanced myelodysplastic syndrome (MDS) received 20 courses of MTA. The median age of the patients was 55 years (20-70 years). Two patients (12%) achieved complete remission. The median overall survival was 8.2 weeks. Five patients (29%) developed grade 3/4 hepatic transaminitis, including one patient (6%) who died with hepatic venoocclusive disease. Conclusions: MTA was moderately effective and associated with significant toxicity in patients with refractory AML.
AB - Purpose: Mylotarg, a humanized anti-CD33 antibody linked to an antitumor antibiotic, is approved for the treatment of patients with relapsed acute myeloid leukemia (AML). Topotecan and cytarabine (ara-C) is an effective anti-AML regimen. A pilot study of Mylotarg combined with topotecan and ara-C (MTA) was conducted in patients with refractory AML. Methods: MTA consisted of Mylotarg 9 mg/m2 intravenously (i.v.) over 2 h on day 1, ara-C 1 g/m2 over 2 h i.v. on days 1 through 5, and topotecan 1.25 mg/m2 by continuous infusion i.v. on days 1 through 5. Results: A group of 17 patients (9 primary resistant, 8 relapsed) with AML or advanced myelodysplastic syndrome (MDS) received 20 courses of MTA. The median age of the patients was 55 years (20-70 years). Two patients (12%) achieved complete remission. The median overall survival was 8.2 weeks. Five patients (29%) developed grade 3/4 hepatic transaminitis, including one patient (6%) who died with hepatic venoocclusive disease. Conclusions: MTA was moderately effective and associated with significant toxicity in patients with refractory AML.
KW - Acute myeloid leukemia
KW - Cytarabine
KW - Mylotarg
KW - Refractory
KW - Topotecan
UR - http://www.scopus.com/inward/record.url?scp=0036453018&partnerID=8YFLogxK
U2 - 10.1007/s00280-002-0539-y
DO - 10.1007/s00280-002-0539-y
M3 - Article
C2 - 12451477
AN - SCOPUS:0036453018
SN - 0344-5704
VL - 50
SP - 497
EP - 500
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
IS - 6
ER -
